About
Products
Pipeline
Partnering
Investors and Media
Stock Information
Financial News
Reports & Presentations
Financial Calendar
Corporate Governance
Annual General Meeting
IR Contact & Service
Contact
Press Releases
Stock Information
Stock Quote and Chart
Listing Information
Financial News and Ad Hoc Releases
Webcast & Presentations
Financial Reporting
Annual Reports
Half Year Report
Financial Calendar
Perfect Holding SA – Historical Information
Corporate Governance
Annual General Meeting
IR Contact & Service
Ad-hoc Releases
select year
select year
2024
2023
2022
Date
Headline
PDF
May 24, 2024
Curatis Holding AG publishes Annual Report of the (then still named) Kinarus Group for FY2023 and announces appointment of Chief Financial Officer
Apr 26, 2024
Business Combination of Kinarus Therapeutics Holding AG (now renamed to Curatis Holding AG) and Curatis AG completed
Apr 17, 2024
Kinarus Therapeutics Holding AG publishes FY2023 Financial Statements and announces details on Business Combination with Curatis AG and Reverse Share Split
Feb 28, 2024
Publication of unaudited financial statements of Kinarus Therapeutics Holding AG (only) for FY2023
Feb 6, 2024
Courts of Basel-Stadt have revoked bankruptcy of Kinarus Therapeutics Holding AG
Jan 29, 2024
Kinarus Therapeutics Holding AG in Liquidation and Curatis AG propose to combine companies and reverse bankruptcy procedures of Kinarus Therapeutics Holding AG in Liquidation
Date
Headline
PDF
Sep 25, 2023
Kinarus Therapeutics has decided to file for bankruptcy
Aug 30, 2023
Kinarus Therapeutics Group Reports First Half 2023 Financial Results
Aug 25, 2023
Kinarus Therapeutics signed licensing agreement to extend cash for operations
Jun 27, 2023
Kinarus Therapeutics signed subordinated bridge loans to ensure further liquidity
May 31, 2023
Kinarus Therapeutics Group Reports 2022 Annual Results
May 11, 2023
Kinarus Therapeutics signed CHF1.5 million convertible loan agreement with ChaoDian (Hangzhou) Investment Management
May 5, 2023
Kinarus Therapeutics Reports Key Unaudited Full Year 2022 Figures
Apr 28, 2023
Kinarus Therapeutics Holding AG ("Kinarus") receives deadline extension from SER for publication of its 2022 annual financial report
Date
Headline
PDF
Sep 30, 2022
Kinarus Therapeutics Announces Discontinuation of the Phase 2 KINETIC Study of KIN001 in Hospitalized COVID-19 Patients Following a Prespecified Interim Analysis of Efficacy and Safety
Aug 31, 2022
Kinarus Therapeutics Reports H1 2022 Financial Results and Provides Corporate Update
Aug 29, 2022
Kinarus Therapeutics initiates KIN001 Phase II KINFAST clinical trial in COVID-19 outpatients
Aug 22, 2022
Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville
Aug 22, 2022
Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19
Jun 24, 2022
Kinarus Therapeutics to host KOL event on Monday, June 27, to discuss therapies in wet Age-Related Macular Degeneration and potential advantages of KIN001
Corporate News
select year
select year
2024
2023
2022
2021
Date
Headline
PDF
Jul 25, 2024
Curatis Holding AG: Initiation of Coverage and Publication of Equity Research Report by valuationLAB
Jun 21, 2024
Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors
Apr 17, 2024
Q&A on the Reverse Share Split
Mar 1, 2024
Minutes of the Extraordinary General Meeting of Shareholders
Mar 1, 2024
Extraordinary General Meeting of Kinarus Holding approved all resolutions relating to the envisaged Business Combination with Curatis
Feb 8, 2024
Einladung zur ausserordentlichen Generalversammlung 2024
Feb 8, 2024
Invitation to the extraordinary general meeting
Date
Headline
PDF
Jul 12, 2023
Kinarus Therapeutics Announces Personnel Changes
Jun 29, 2023
Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting
Jun 2, 2023
Kinarus Therapeutics Publishes Invitation to the 2023 Annual General Meeting
N/A
Feb 21, 2023
Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update
Jan 17, 2023
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan
Date
Headline
PDF
Dec 6, 2022
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5
Nov 22, 2022
Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001
Nov 16, 2022
Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China
Nov 4, 2022
Kinarus Therapeutics Provides Strategic Update
Jun 20, 2022
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 and Variants of Concern
Jun 10, 2022
Kinarus Therapeutics Announces Name Change and Commences Trading on the SIX Swiss Exchange under ticker “KNRS”
Jun 3, 2022
Perfect Holding Completes Reverse Takeover Transaction with Kinarus
May 10, 2022
Positive Preclinical Data for KIN001 in wet Age-Related Macular Degeneration - Plans for Clinical Development
Apr 26, 2022
Kinarus Receives Grant of Key U.S. Patent for its Lead Therapeutic Candidate
Apr 20, 2022
Kinarus Shareholders Approve Reverse Takeover by Perfect Holding SA
Apr 12, 2022
Kinarus Receives Positive Recommendation from DSMB to Continue Phase 2 Trial in COVID-19
Mar 30, 2022
Kinarus Announces Signing of a Transaction Agreement with Perfect Holding
Date
Headline
PDF
Dec 13, 2021
Kinarus receives 7 Million CHF Grant from the Swiss Federal Funding Programme for COVID-19 Medicines
Sep 9, 2021
Kinarus Secures CHF 57 Million Capital Commitment
Aug 23, 2021
Preclinical Data Confirm Triple Mechanism of Action of Lead Compound KIN001 in COVID-19
Aug 17, 2021
Signature of a Memorandum of Understanding with Perfect Holding SA
Apr 26, 2021
Kinarus further strengthens its leadership with two reputed industry experts
N/A
Apr 13, 2021
First Hospitalized COVID-19 Patient Dosed with KIN001 in Phase 2 Study
Apr 13, 2021
Kinarus AG: First Hospitalized COVID-19 Patient Dosed with KIN001 in Phase 2 Study
N/A
Jan 21, 2021
Kinarus appoints Thierry Fumeaux, MD, as Chief Medical Officer